NewAmsterdam Pharma (NAMS) Competitors $26.60 -0.30 (-1.12%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$26.62 +0.01 (+0.06%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, and LEGNShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors Qiagen BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Qiagen (NYSE:QGEN) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Which has better earnings & valuation, QGEN or NAMS? Qiagen has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.18$83.59M$1.6927.25NewAmsterdam Pharma$45.56M65.76-$241.60M-$1.62-16.42 Is QGEN or NAMS more profitable? Qiagen has a net margin of 18.30% compared to NewAmsterdam Pharma's net margin of -259.07%. Qiagen's return on equity of 14.77% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% NewAmsterdam Pharma -259.07%-27.27%-25.00% Do insiders & institutionals have more ownership in QGEN or NAMS? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, QGEN or NAMS? Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Does the media prefer QGEN or NAMS? In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Qiagen. MarketBeat recorded 16 mentions for NewAmsterdam Pharma and 14 mentions for Qiagen. NewAmsterdam Pharma's average media sentiment score of 1.06 beat Qiagen's score of 1.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer QGEN or NAMS? Qiagen currently has a consensus target price of $49.69, indicating a potential upside of 7.87%. NewAmsterdam Pharma has a consensus target price of $41.55, indicating a potential upside of 56.19%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummaryQiagen and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.03B$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-16.4223.7675.1126.20Price / Sales65.76564.68470.8391.87Price / CashN/A169.2537.0859.91Price / Book3.245.3912.116.28Net Income-$241.60M$32.95M$3.29B$270.85M7 Day Performance-1.48%2.61%1.58%3.58%1 Month Performance6.40%9.87%7.88%6.67%1 Year Performance66.25%1.49%61.66%27.73% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.3901 of 5 stars$26.60-1.1%$41.55+56.2%+64.6%$3.03B$45.56M-16.424News CoverageInsider TradeHigh Trading VolumeQGENQiagen4.4438 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$1.98B27.495,765Positive NewsBBIOBridgeBio Pharma4.3446 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$221.90M-12.66400Positive NewsMRNAModerna4.5286 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.24B-3.205,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1875 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.807 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.12B$4.44B21.379,000High Trading VolumeROIVRoivant Sciences2.8249 of 5 stars$11.93-0.1%$16.38+37.3%+16.4%$8.15B$29.05M-17.04860News CoverageOptions VolumeRVMDRevolution Medicines4.2575 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst RevisionGap UpGRFSGrifols3.8709 of 5 stars$9.97+1.0%$10.30+3.3%+9.0%$6.85B$7.81B8.5223,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1918 of 5 stars$103.15-1.0%$101.57-1.5%+98.6%$6.85B$130.13M-34.27140Positive NewsLEGNLegend Biotech3.2909 of 5 stars$34.73+1.0%$74.22+113.7%-32.0%$6.41B$627.24M-39.472,609Positive News Related Companies and Tools Related Companies Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
